Delivery Order SPE2DB22D2214-SPE2DB22FS2PF
Award Date 6/9/22
Potential Completion Date 6/10/22
Potential Value $112K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML medical supplies. The $99,634.60 contract has a completion date of December 22, 2023 and was awarded on December 21, 2023. This order is part of Amerisourcebergen's existing indefinite delivery contract with DLA to provide pharmaceuticals and medical supplies, primarily in support of...
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,684.96 to supply HEPLISAV-B 20 mcg/0.5 mL syringes on May 27, 2025. The order is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award does not utilize a set-aside designation and was competitively awarded. This delivery order is a child contract under...
- The Defense Logistics Agency (DLA) awarded a $72,453.28 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of October 22, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,559.94 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. This non-competitive delivery order, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, represents a firm fixed-price purchase of hepatitis B vaccine syringes to support federal medical supply needs. The award was fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,171.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of December 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96, with an ultimate completion date of June 25, 2025. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The product will be performed at AmerisourceBergen's Conshohocken location. HEPLISAV-B is a recombinant...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The order has a potential value of $103,308.00 and a completion date of November 1, 2021. Amerisourcebergen Drug Corp is a prime contractor that has received multiple federal contract awards to provide pharmaceutical products and medical supplies to...
- The Defense Logistics Agency (DLA) awarded a $37,755.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 8, 2025, with completion due by December 9, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine, and this delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation....
- The Defense Logistics Agency awarded a $61,478.90 delivery order to AmerisourceBergen Drug Corp on December 23, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of December 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's competitive standing in the federal...